Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Karyopharm Therapeutics (KPTI) Debt to Equity (2024 - 2025)

Karyopharm Therapeutics' Debt to Equity history spans 2 years, with the latest figure at -$0.4 for Q4 2025.

  • For Q4 2025, Debt to Equity rose 22.26% year-over-year to -$0.4; the TTM value through Dec 2025 reached -$0.4, up 22.26%, while the annual FY2025 figure was -$0.4, 22.26% up from the prior year.
  • Debt to Equity reached -$0.4 in Q4 2025 per KPTI's latest filing, down from -$0.36 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of -$0.36 in Q3 2025 to a low of -$0.71 in Q2 2024.